The	O
latency	O
pattern	O
of	O
Epstein-Barr	O
virus	O
infection	O
and	O
viral	O
IL-10	B-protein
expression	O
in	O
cutaneous	B-cell_type
natural	I-cell_type
killer/T-cell	I-cell_type
lymphomas	I-cell_type
.	O

The	O
nasal	B-cell_type
type	I-cell_type
,	I-cell_type
extranodal	I-cell_type
natural	I-cell_type
killer	I-cell_type
or	I-cell_type
T	I-cell_type
(	I-cell_type
NK/T	I-cell_type
)	I-cell_type
-cell	I-cell_type
lymphoma	I-cell_type
is	O
usually	O
associated	O
with	O
latent	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
EBV	O
gene	O
expression	O
patterns	O
in	O
vivo	O
,	O
we	O
examined	O
eight	O
patients	O
with	O
cutaneous	O
EBV-related	O
NK/T-cell	O
lymphomas	O
,	O
including	O
six	O
patients	O
with	O
a	O
NK-cell	O
phenotype	O
and	O
two	O
patients	O
with	O
a	O
T-cell	O
phenotype	O
.	O

The	O
implication	O
of	O
EBV	O
in	O
the	O
skin	O
lesions	O
was	O
determined	O
by	O
the	O
presence	O
of	O
EBV-DNA	B-DNA
,	O
EBV-encoded	B-RNA
nuclear	I-RNA
RNA	I-RNA
(	O
EBER	B-RNA
)	O
and	O
a	O
clonality	O
of	O
EBV-DNA	B-DNA
fragments	I-DNA
containing	O
the	O
terminal	B-DNA
repeats	I-DNA
.	O

Transcripts	O
of	O
EBV-encoded	B-DNA
genes	I-DNA
were	O
screened	O
by	O
reverse	O
transcription-	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
,	O
and	O
confirmed	O
by	O
Southern	O
blot	O
hybridization	O
.	O

The	O
expression	O
of	O
EBV-related	B-protein
antigens	I-protein
was	O
examined	O
by	O
immunostaining	O
using	O
paraffin-embedded	O
tissue	O
sections	O
and	O
cell	O
pellets	O
of	O
EBV-positive	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Our	O
study	O
demonstrated	O
that	O
all	O
samples	O
from	O
the	O
patients	O
contained	O
EBV	B-RNA
nuclear	I-RNA
antigen	I-RNA
(	I-RNA
EBNA	I-RNA
)	I-RNA
-1	I-RNA
mRNA	I-RNA
which	O
was	O
transcribed	O
using	O
the	O
Q	B-DNA
promoter	I-DNA
,	O
whereas	O
both	O
the	O
Q	B-DNA
promoter	I-DNA
and	O
another	O
upstream	B-DNA
promoter	I-DNA
(	O
Cp/Wp	B-DNA
)	O
were	O
used	O
in	O
EBV-positive	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
B95.8	B-cell_line
,	O
Raji	B-cell_line
and	O
Jiyoye	B-cell_line
.	O

Latent	B-RNA
membrane	I-RNA
protein-1	I-RNA
(	I-RNA
LMP-1	I-RNA
)	I-RNA
mRNA	I-RNA
was	O
detected	O
in	O
seven	O
of	O
eight	O
patients	O
and	O
all	O
cell	B-cell_line
lines	I-cell_line
,	O
whereas	O
EBNA-2	B-RNA
transcripts	I-RNA
were	O
found	O
only	O
in	O
the	O
cell	B-cell_line
lines	I-cell_line
.	O

Immunostaining	O
showed	O
no	O
LMP-1	B-protein
,	I-protein
EBNA-2	I-protein
or	I-protein
ZEBRA	I-protein
antigens	I-protein
in	O
the	O
paraffin-embedded	O
tissue	O
sections	O
,	O
although	O
they	O
were	O
positive	O
in	O
the	O
cell	B-cell_line
line	I-cell_line
cells	I-cell_line
.	O

Latent	B-RNA
BHRF1	I-RNA
transcripts	I-RNA
encoding	O
bcl-2	B-RNA
homologue	I-RNA
and	O
BCRF1	B-RNA
transcripts	I-RNA
encoding	O
viral	B-protein
interleukin	I-protein
(	I-protein
vIL	I-protein
)	I-protein
-10	I-protein
were	O
detected	O
in	O
one	O
and	O
two	O
of	O
eight	O
patients	O
,	O
respectively	O
.	O

A	O
patient	O
with	O
NK-cell	O
lymphoma	O
expressing	O
both	O
transcripts	O
died	O
of	O
rapid	O
progression	O
of	O
the	O
illness	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
restricted	O
expression	O
of	O
the	O
latency-associated	B-DNA
EBV	I-DNA
genes	I-DNA
and	O
the	O
production	O
of	O
vIL-10	B-RNA
and	I-RNA
bcl-2	I-RNA
homologue	I-RNA
may	O
favour	O
tumour	O
growth	O
,	O
evading	O
the	O
host	O
immune	O
surveillance	O
.	O

Copyright	O
2001	O
Cancer	O
Research	O
Campaign	O
.	O

British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
2001	NULL
)	NULL
84	NULL
(	NULL
7	NULL
)	NULL
,	NULL
920-925	NULL
©2001	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
doi	NULL
:	NULL
10.1054/	NULL
bjoc.2000.1687	NULL
,	NULL
available	NULL
online	NULL
at	NULL
http	NULL
:	NULL
/www.idealibrary.com	NULL
on	NULL
IDE	NULL
kill	NULL
?	NULL

http	NULL
:	NULL
//WWW.bjcancer.C0m	NULL
The	NULL
latency	NULL
pattern	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
infection	NULL
and	NULL
viral	NULL
IL-10	NULL
expression	NULL
in	NULL
cutaneous	NULL
natural	NULL
killer/T-cell	NULL
lymphomas	NULL
Z-G	NULL
Xu	NULL
'	NULL
,	NULL
K	NULL
Iwatsuki	NULL
,	NULL
N	NULL
Oyama	NULL
,	NULL
M	NULL
Ohtsuka	NULL
'	NULL
,	NULL
M	NULL
Satoh	NULL
,	NULL
S	NULL
Kikuchi	NULL
'	NULL
,	NULL
H	NULL
Akiba	NULL
'	NULL
and	NULL
F	NULL
Kaneko	NULL
'	NULL
'Department	NULL
of	NULL
Dermatology	NULL
,	NULL
Fukushima	NULL
Medical	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Hikarigaoka	NULL
1	NULL
,	NULL
Fukushima	NULL
960-1295	NULL
,	NULL
Japan	NULL
Department	NULL
of	NULL
Dermatology	NULL
,	NULL
Graduate	NULL
School	NULL
of	NULL
Medicine	NULL
and	NULL
Dentistry	NULL
,	NULL
Okayama	NULL
University	NULL
Graduate	NULL
Schools	NULL
,	NULL
2-5-1	NULL
Shikata-cho	NULL
,	NULL
Okayama	NULL
700-8558	NULL
,	NULL
Japan	NULL
Summary	NULL
The	NULL
nasal	NULL
type	NULL
,	NULL
extranodal	NULL
natural	NULL
killer	NULL
or	NULL
T	NULL
(	NULL
NK/T	NULL
)	NULL
-cell	NULL
is	NULL
usually	NULL
associated	NULL
with	NULL
latent	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
infection	NULL
.	NULL

In	NULL
order	NULL
to	NULL
elucidate	NULL
the	NULL
EBV	NULL
gene	NULL
expression	NULL
patterns	NULL
in	NULL
vivo	NULL
,	NULL
we	NULL
examined	NULL
eight	NULL
patients	NULL
with	NULL
cutaneous	NULL
EBV-related	NULL
NK/T-cell	NULL
lymphomas	NULL
,	NULL
including	NULL
six	NULL
patients	NULL
with	NULL
a	NULL
NK-cell	NULL
phenotype	NULL
and	NULL
two	NULL
patients	NULL
with	NULL
a	NULL
T-cell	NULL
phenotype	NULL
.	NULL

The	NULL
implication	NULL
of	NULL
EBV	NULL
in	NULL
the	NULL
skin	NULL
lesions	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
EBV-DNA	NULL
,	NULL
EBV-encoded	NULL
nuclear	NULL
RNA	NULL
(	NULL
EBER	NULL
)	NULL
and	NULL
a	NULL
clonality	NULL
of	NULL
EBV-DNA	NULL
fragments	NULL
containing	NULL
the	NULL
terminal	NULL
repeats	NULL
.	NULL

Transcripts	NULL
of	NULL
EBV-encoded	NULL
genes	NULL
were	NULL
screened	NULL
by	NULL
reverse	NULL
transcription-	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
RT-PCR	NULL
)	NULL
,	NULL
and	NULL
confirmed	NULL
by	NULL
Southern	NULL
blot	NULL
hybridization	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
EBV-related	NULL
antigens	NULL
was	NULL
examined	NULL
by	NULL
immunostaining	NULL
using	NULL
paraffin-embedded	NULL
tissue	NULL
sections	NULL
and	NULL
cell	NULL
pellets	NULL
of	NULL
EBV-positive	NULL
cell	NULL
lines	NULL
.	NULL

Our	NULL
study	NULL
demonstrated	NULL
that	NULL
all	NULL
samples	NULL
from	NULL
the	NULL
patients	NULL
contained	NULL
EBV	NULL
nuclear	NULL
antigen	NULL
(	NULL
EBNA	NULL
)	NULL
-1	NULL
mRNA	NULL
which	NULL
was	NULL
transcribed	NULL
using	NULL
the	NULL
Q	NULL
promoter	NULL
,	NULL
whereas	NULL
both	NULL
the	NULL
Q	NULL
promoter	NULL
and	NULL
another	NULL
upstream	NULL
promoter	NULL
(	NULL
Cp/Wp	NULL
)	NULL
were	NULL
used	NULL
in	NULL
EBV-positive	NULL
cell	NULL
lines	NULL
,	NULL
B95.8	NULL
,	NULL
Raji	NULL
and	NULL
Jiyoye	NULL
.	NULL

Latent	NULL
membrane	NULL
protein-1	NULL
(	NULL
LMP-1	NULL
)	NULL
mRNA	NULL
was	NULL
detected	NULL
in	NULL
seven	NULL
of	NULL
eight	NULL
patients	NULL
and	NULL
all	NULL
cell	NULL
lines	NULL
,	NULL
whereas	NULL
EBNA-2	NULL
transcripts	NULL
were	NULL
found	NULL
only	NULL
in	NULL
the	NULL
cell	NULL
lines	NULL
.	NULL

Immunostaining	NULL
showed	NULL
no	NULL
LMP-1	NULL
,	NULL
EBNA-2	NULL
or	NULL
ZEBRA	NULL
antigens	NULL
in	NULL
the	NULL
paraffin-embedded	NULL
tissue	NULL
sections	NULL
,	NULL
although	NULL
they	NULL
were	NULL
positive	NULL
in	NULL
the	NULL
cell	NULL
line	NULL
cells	NULL
.	NULL

Latent	NULL
BHRF1	NULL
transcripts	NULL
encoding	NULL
bel-2	NULL
homologue	NULL
and	NULL
BCRF1	NULL
transcripts	NULL
encoding	NULL
viral	NULL
interleukin	NULL
(	NULL
vIL	NULL
)	NULL
-10	NULL
were	NULL
detected	NULL
in	NULL
one	NULL
and	NULL
two	NULL
of	NULL
eight	NULL
patients	NULL
,	NULL
respectively	NULL
.	NULL

A	NULL
patient	NULL
with	NULL
NK-cell	NULL
lymphoma	NULL
expressing	NULL
both	NULL
transcripts	NULL
died	NULL
of	NULL
rapid	NULL
progression	NULL
of	NULL
the	NULL
illness	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
restricted	NULL
expression	NULL
of	NULL
the	NULL
latency-associated	NULL
EBV	NULL
genes	NULL
and	NULL
the	NULL
production	NULL
of	NULL
vIL-10	NULL
and	NULL
bel-2	NULL
homologue	NULL
may	NULL
favour	NULL
tumour	NULL
growth	NULL
,	NULL
evading	NULL
the	NULL
host	NULL
immune	NULL
surveillance	NULL
.	NULL

©	NULL
2001	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
-	NULL
http	NULL
:	NULL
//www.bjcancer.com	NULL
Keywords	NULL
:	NULL
Epstein-Barr	NULL
virus	NULL
;	NULL
NK/T-cell	NULL
lymphomas	NULL
;	NULL
latency	NULL
;	NULL
viral	NULL
IL-10	NULL
;	NULL
bel-2	NULL
homologue	NULL
;	NULL
LMP	NULL
;	NULL
EBNA	NULL
Several	NULL
lines	NULL
of	NULL
evidence	NULL
have	NULL
shown	NULL
the	NULL
association	NULL
of	NULL
latent	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
infection	NULL
with	NULL
the	NULL
nasal-type	NULL
,	NULL
extranodal	NULL
natural	NULL
killer	NULL
or	NULL
T	NULL
(	NULL
NK/T	NULL
)	NULL
-cell	NULL
lymphoma	NULL
which	NULL
occurs	NULL
predominantly	NULL
in	NULL
Asia	NULL
and	NULL
Mexico	NULL
(	NULL
Harabuchi	NULL
et	NULL
al	NULL
,	NULL
1990	NULL
;	NULL
Su	NULL
et	NULL
al	NULL
,	NULL
1991	NULL
;	NULL
Jaffe	NULL
et	NULL
al	NULL
,	NULL
1996	NULL
;	NULL
Harris	NULL
et	NULL
al	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

This	NULL
type	NULL
of	NULL
lymphoma	NULL
primarily	NULL
affects	NULL
the	NULL
nasal	NULL
cavity	NULL
and	NULL
skin	NULL
,	NULL
exhibiting	NULL
histopathological	NULL
features	NULL
of	NULL
angiodestructive	NULL
infiltration	NULL
and	NULL
tissue	NULL
necrosis	NULL
(	NULL
Su	NULL
and	NULL
Hsieh	NULL
,	NULL
1992	NULL
;	NULL
Jaffe	NULL
et	NULL
al	NULL
,	NULL
1996	NULL
;	NULL
Chan	NULL
et	NULL
al	NULL
,	NULL
1997	NULL
;	NULL
Iwatsuki	NULL
et	NULL
al	NULL
,	NULL
1997	NULL
)	NULL
,	NULL
and	NULL
a	NULL
frequent	NULL
complication	NULL
of	NULL
haemophagocytic	NULL
syndrome	NULL
(	NULL
Jaffe	NULL
et	NULL
al	NULL
,	NULL
1983	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
EBV-DNA	NULL
,	NULL
EBV-encoded	NULL
nuclear	NULL
RNA	NULL
(	NULL
EBER	NULL
)	NULL
is	NULL
usually	NULL
present	NULL
in	NULL
the	NULL
neoplastic	NULL
cells	NULL
.	NULL

The	NULL
detection	NULL
of	NULL
these	NULL
molecules	NULL
,	NULL
therefore	NULL
,	NULL
provides	NULL
a	NULL
diagnostic	NULL
clue	NULL
for	NULL
this	NULL
disorder	NULL
.	NULL

Although	NULL
viral	NULL
proteins	NULL
such	NULL
as	NULL
latent	NULL
membrane	NULL
protein	NULL
(	NULL
LMP	NULL
)	NULL
and	NULL
EBV	NULL
nuclear	NULL
antigen	NULL
(	NULL
EBNA	NULL
)	NULL
may	NULL
have	NULL
a	NULL
crucial	NULL
role	NULL
for	NULL
EBV-induced	NULL
cell	NULL
transformation	NULL
(	NULL
Wang	NULL
et	NULL
al	NULL
,	NULL
1985	NULL
;	NULL
Rickinson	NULL
et	NULL
al	NULL
,	NULL
1987	NULL
)	NULL
,	NULL
the	NULL
in	NULL
vivo	NULL
expression	NULL
pattern	NULL
of	NULL
the	NULL
virus-related	NULL
molecules	NULL
has	NULL
not	NULL
yet	NULL
been	NULL
clarified	NULL
in	NULL
the	NULL
nasal	NULL
type	NULL
,	NULL
NK/T-cell	NULL
lymphoma	NULL
.	NULL

Received	NULL
4	NULL
April	NULL
2000	NULL
Revised	NULL
6	NULL
December	NULL
2000	NULL
Accepted	NULL
7	NULL
December	NULL
2000	NULL
Correspondence	NULL
to	NULL
:	NULL
K	NULL
Iwatsuki	NULL
;	NULL
Email	NULL
:	NULL
keijiiwa	NULL
@	NULL
fmu.ac.jp	NULL
920	NULL
EBV-infected	NULL
cells	NULL
and	NULL
neoplasms	NULL
generally	NULL
show	NULL
one	NULL
of	NULL
three	NULL
different	NULL
patterns	NULL
of	NULL
latency-associated	NULL
viral	NULL
gene	NULL
expression	NULL
:	NULL
latency	NULL
I	NULL
,	NULL
II	NULL
and	NULL
III	NULL
(	NULL
Rowe	NULL
et	NULL
al	NULL
,	NULL
1987	NULL
;	NULL
Kerr	NULL
et	NULL
al	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

EBV-infected	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
and	NULL
lymphoproliferative	NULL
diseases	NULL
arising	NULL
in	NULL
immunocompromised	NULL
hosts	NULL
express	NULL
all	NULL
nine	NULL
latency-associated	NULL
viral	NULL
proteins	NULL
,	NULL
including	NULL
six	NULL
EBNAs	NULL
(	NULL
1	NULL
,	NULL
2	NULL
,	NULL
3A	NULL
,	NULL
3B	NULL
,	NULL
3C	NULL
and	NULL
LP	NULL
)	NULL
and	NULL
three	NULL
LMPs	NULL
(	NULL
1	NULL
,	NULL
2A	NULL
and	NULL
2B	NULL
)	NULL
(	NULL
Rowe	NULL
et	NULL
al	NULL
,	NULL
1987	NULL
;	NULL
Young	NULL
et	NULL
al	NULL
,	NULL
1989	NULL
;	NULL
Hamilton-Dutoit	NULL
et	NULL
al	NULL
,	NULL
1993	NULL
)	NULL
.	NULL

This	NULL
pattern	NULL
of	NULL
EBV	NULL
gene	NULL
expression	NULL
is	NULL
designated	NULL
as	NULL
latency	NULL
IIL	NULL
.	NULL

In	NULL
latency	NULL
II	NULL
,	NULL
as	NULL
noted	NULL
in	NULL
EBV-associated	NULL
Hodgkin	NULL
's	NULL
disease	NULL
and	NULL
nasopharyngeal	NULL
carcinoma	NULL
,	NULL
the	NULL
EBNA-1	NULL
,	NULL
LMP-1	NULL
and	NULL
LMP-2	NULL
genes	NULL
but	NULL
not	NULL
other	NULL
EBNA	NULL
genes	NULL
are	NULL
transcribed	NULL
(	NULL
Brooks	NULL
et	NULL
al	NULL
,	NULL
1992	NULL
;	NULL
Deacon	NULL
et	NULL
al	NULL
,	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
latency	NULL
I	NULL
,	NULL
EBV-infected	NULL
cells	NULL
express	NULL
only	NULL
EBNA-1	NULL
,	NULL
which	NULL
is	NULL
essential	NULL
for	NULL
episomal	NULL
replication	NULL
.	NULL

This	NULL
pattern	NULL
is	NULL
found	NULL
in	NULL
Burkitt	NULL
's	NULL
lymphomas	NULL
(	NULL
Tao	NULL
et	NULL
al	NULL
,	NULL
1998	NULL
)	NULL
and	NULL
gastric	NULL
carcinomas	NULL
(	NULL
Sugiura	NULL
et	NULL
al	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
differences	NULL
in	NULL
the	NULL
three	NULL
patterns	NULL
of	NULL
EBV	NULL
gene	NULL
transcription	NULL
are	NULL
determined	NULL
by	NULL
cell	NULL
phenotypes	NULL
and	NULL
the	NULL
usage	NULL
of	NULL
gene	NULL
promoters	NULL
.	NULL

The	NULL
EBNA	NULL
genes	NULL
are	NULL
transcribed	NULL
as	NULL
a	NULL
single	NULL
polycistronic	NULL
RNA	NULL
molecule	NULL
which	NULL
is	NULL
spliced	NULL
to	NULL
give	NULL
rise	NULL
to	NULL
expression	NULL
of	NULL
the	NULL
individual	NULL
EBNA	NULL
molecules	NULL
.	NULL

The	NULL
transcription	NULL
in	NULL
latency	NULL
III	NULL
is	NULL
initiated	NULL
from	NULL
a	NULL
promoter	NULL
,	NULL
located	NULL
within	NULL
the	NULL
BamHI	NULL
regions	NULL
C	NULL
and	NULL
W	NULL
(	NULL
the	NULL
C/W	NULL
promoter	NULL
,	NULL
Cp/Wp	NULL
)	NULL
and	NULL
results	NULL
in	NULL
a	NULL
Y/U/K-spliced	NULL
EBNA1	NULL
mRNA	NULL
,	NULL
whereas	NULL
transcription	NULL
of	NULL
only	NULL
EBNA-1	NULL
in	NULL
latency	NULL
I	NULL
is	NULL
driven	NULL
by	NULL
a	NULL
downstream	NULL
promoter	NULL
located	NULL
in	NULL
the	NULL
BamHI	NULL
F	NULL
and	NULL
Q	NULL
regions	NULL
(	NULL
the	NULL
Q	NULL
promoter	NULL
,	NULL
Qp	NULL
)	NULL
,	NULL
generating	NULL
a	NULL
Q/U/K-spliced	NULL
mRNA	NULL
without	NULL
other	NULL
EBNA	NULL
products	NULL
(	NULL
Sample	NULL
et	NULL
al	NULL
,	NULL
1991	NULL
;	NULL
Schaefer	NULL
et	NULL
al	NULL
,	NULL
1991	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
latency-associated	NULL
genes	NULL
,	NULL
EBV	NULL
encodes	NULL
proteins	NULL
that	NULL
modulate	NULL
the	NULL
host	NULL
's	NULL
immune	NULL
system	NULL
and	NULL
inhibit	NULL
apoptosis	NULL
.	NULL

The	NULL
BHRF1	NULL
gene	NULL
has	NULL
partial	NULL
sequence	NULL
homology	NULL
to	NULL
the	NULL
human	NULL
bel-2	NULL
gene	NULL
(	NULL
Henderson	NULL
et	NULL
al	NULL
,	NULL
1993	NULL
)	NULL
and	NULL
the	NULL
BCRF1	NULL
gene	NULL
encodes	NULL
viral	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-10	NULL
(	NULL
Moore	NULL
et	NULL
al	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
BARF1l-encoded	NULL
protein	NULL
functions	NULL
as	NULL
a	NULL
soluble	NULL
receptor	NULL
for	NULL
colony-stimulating	NULL
factor	NULL
1	NULL
which	NULL
inhibits	NULL
interferon-secretion	NULL
from	NULL
mononuclear	NULL
cells	NULL
(	NULL
Cohen	NULL
et	NULL
al	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
these	NULL
molecules	NULL
may	NULL
be	NULL
implicated	NULL
in	NULL
the	NULL
outgrowth	NULL
of	NULL
EBV-infected	NULL
cells	NULL
.	NULL

In	NULL
order	NULL
to	NULL
clarify	NULL
the	NULL
latency	NULL
pattern	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
EBV-encoded	NULL
immunoregulatory	NULL
molecules	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
biopsy	NULL
specimens	NULL
from	NULL
eight	NULL
Japanese	NULL
patients	NULL
with	NULL
EBV-related	NULL
cutaneous	NULL
NK/T-cell	NULL
lymphomas	NULL
.	NULL

We	NULL
investigated	NULL
transcripts	NULL
of	NULL
latency-associated	NULL
EBV	NULL
genes	NULL
,	NULL
the	NULL
BHRF1	NULL
(	NULL
bel-2	NULL
homologue	NULL
)	NULL
and	NULL
the	NULL
BCRFI	NULL
(	NULL
viral	NULL
IL-10	NULL
)	NULL
genes	NULL
in	NULL
tumour	NULL
tissues	NULL
by	NULL
reverse-transcription	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
RT-PCR	NULL
)	NULL
and	NULL
Southern	NULL
blot	NULL
hybridization	NULL
.	NULL

PATIENTS	NULL
,	NULL
MATERIALS	NULL
AND	NULL
METHODS	NULL
Patients	NULL
Eight	NULL
patients	NULL
with	NULL
nasal-type	NULL
,	NULL
extranodal	NULL
NK/T-cell	NULL
lymphoma	NULL
including	NULL
six	NULL
patients	NULL
with	NULL
a	NULL
NK-cell	NULL
phenotype	NULL
and	NULL
two	NULL
with	NULL
a	NULL
T-cell	NULL
phenotype	NULL
were	NULL
enrolled	NULL
in	NULL
the	NULL
study	NULL
.	NULL

The	NULL
diagnoses	NULL
were	NULL
confirmed	NULL
by	NULL
immunophenotyping	NULL
of	NULL
the	NULL
infiltrating	NULL
cells	NULL
and	NULL
the	NULL
detection	NULL
of	NULL
EBV-DNA	NULL
,	NULL
EBV-encoded	NULL
RNA	NULL
(	NULL
EBER	NULL
)	NULL
and	NULL
a	NULL
clonality	NULL
of	NULL
EBV-DNA	NULL
fragment	NULL
containing	NULL
the	NULL
terminal	NULL
repeat	NULL
as	NULL
described	NULL
below	NULL
.	NULL

The	NULL
clinical	NULL
manifestations	NULL
of	NULL
two	NULL
patients	NULL
(	NULL
NK3	NULL
and	NULL
Tl	NULL
)	NULL
have	NULL
been	NULL
reported	NULL
in	NULL
detail	NULL
elsewhere	NULL
(	NULL
Ohtsuka	NULL
et	NULL
al	NULL
,	NULL
1999	NULL
)	NULL
.	NULL

Tumour	NULL
samples	NULL
and	NULL
cell	NULL
lines	NULL
Paraffin-embedded	NULL
skin	NULL
biopsy	NULL
specimens	NULL
from	NULL
the	NULL
eight	NULL
patients	NULL
were	NULL
examined	NULL
for	NULL
immunophenotypes	NULL
,	NULL
EBER	NULL
and	NULL
EBV	NULL
antigens	NULL
,	NULL
including	NULL
LMP-1	NULL
,	NULL
EBNA2	NULL
and	NULL
ZEBRA	NULL
.	NULL

DNA	NULL
samples	NULL
from	NULL
frozen	NULL
skin	NULL
biopsies	NULL
were	NULL
used	NULL
for	NULL
clonality	NULL
analyses	NULL
of	NULL
T-cell	NULL
receptor	NULL
gene	NULL
rearrangement	NULL
and	NULL
EBV	NULL
terminal	NULL
repeats	NULL
,	NULL
and	NULL
for	NULL
EB	NULL
virus	NULL
antigen	NULL
expression	NULL
by	NULL
NK/T-cell	NULL
lymphomas	NULL
921	NULL
the	NULL
determination	NULL
of	NULL
EBV	NULL
gene	NULL
transcripts	NULL
.	NULL

Two	NULL
established	NULL
EBV-positive	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
lines	NULL
,	NULL
Raji	NULL
and	NULL
Jiyoye	NULL
,	NULL
and	NULL
one	NULL
EBV-transformed	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
,	NULL
B95.8	NULL
,	NULL
served	NULL
as	NULL
positive	NULL
controls	NULL
for	NULL
EBV	NULL
gene	NULL
transcription	NULL
.	NULL

An	NULL
EBV-negative	NULL
T-cell	NULL
line	NULL
,	NULL
Molt	NULL
,	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
for	NULL
RT-PCR	NULL
.	NULL

All	NULL
cell	NULL
lines	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
1	NULL
mM	NULL
glutamine	NULL
,	NULL
100	NULL
U/ml	NULL
penicillin	NULL
and	NULL
100	NULL
U	NULL
mIl~	NULL
'	NULL
streptomycin	NULL
.	NULL

In	NULL
situ	NULL
hybridization	NULL
for	NULL
EBER	NULL
In	NULL
situ	NULL
hybridization	NULL
was	NULL
performed	NULL
on	NULL
paraffin-embedded	NULL
sections	NULL
.	NULL

After	NULL
deparaffinization	NULL
and	NULL
digestion	NULL
with	NULL
0.8	NULL
%	NULL
pepsin	NULL
(	NULL
DAKO	NULL
,	NULL
Glostrup	NULL
)	NULL
,	NULL
the	NULL
sections	NULL
were	NULL
pre-hybridized	NULL
with	NULL
salmon	NULL
sperm	NULL
DNA	NULL
and	NULL
then	NULL
hybridized	NULL
with	NULL
fluorescein	NULL
isothiocyanate	NULL
labelled	NULL
oligonucleotide	NULL
probe	NULL
for	NULL
EBER1	NULL
and	NULL
2	NULL
(	NULL
Novocastra	NULL
,	NULL
Newcastle	NULL
upon	NULL
Tyne	NULL
)	NULL
at	NULL
37°C	NULL
overnight	NULL
.	NULL

After	NULL
post-hybridization	NULL
washing	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
150	NULL
mmol	NULL
17	NULL
'	NULL
sodium	NULL
chloride	NULL
and	NULL
15	NULL
mmol	NULL
17	NULL
sodium	NULL
citrate	NULL
(	NULL
pH	NULL
7.0	NULL
)	NULL
at	NULL
50°C	NULL
,	NULL
the	NULL
specimens	NULL
were	NULL
incubated	NULL
with	NULL
alkaline	NULL
phosphatase-conjugated	NULL
antibody	NULL
to	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
Novocastra	NULL
)	NULL
.	NULL

Positive	NULL
signals	NULL
were	NULL
visualized	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
5-bromo-4-chloro-3-indolylphosphate	NULL
and	NULL
nitroblue	NULL
tetrazolium	NULL
.	NULL

Clonality	NULL
analysis	NULL
of	NULL
EBV	NULL
terminal	NULL
repeats	NULL
Frozen	NULL
tissues	NULL
were	NULL
minced	NULL
on	NULL
ice	NULL
in	NULL
buffer	NULL
containing	NULL
15	NULL
mM	NULL
sodium	NULL
chloride	NULL
,	NULL
15	NULL
mM	NULL
Tris-HCl	NULL
and	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
and	NULL
digested	NULL
at	NULL
37°C	NULL
overnight	NULL
with	NULL
0.025	NULL
%	NULL
proteinase	NULL
K.	NULL
Following	NULL
extraction	NULL
with	NULL
phenol/chloroform	NULL
and	NULL
ethanol	NULL
precipitation	NULL
,	NULL
DNA	NULL
was	NULL
resuspended	NULL
in	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
.	NULL

Five	NULL
g	NULL
DNA	NULL
was	NULL
digested	NULL
with	NULL
BamHI	NULL
and	NULL
then	NULL
separated	NULL
on	NULL
a	NULL
0.8	NULL
%	NULL
agarose	NULL
gel	NULL
.	NULL

The	NULL
DNA	NULL
was	NULL
transferred	NULL
to	NULL
a	NULL
nylon	NULL
membrane	NULL
and	NULL
then	NULL
hybridized	NULL
with	NULL
a	NULL
digoxigenin-labeled	NULL
EBV	NULL
terminal	NULL
fragment	NULL
probe	NULL
,	NULL
an	NULL
Xho-1	NULL
1.9	NULL
kb	NULL
fragment	NULL
(	NULL
Raab-Traub	NULL
and	NULL
Flynn	NULL
,	NULL
1986	NULL
)	NULL
.	NULL

mRNA	NULL
preparation	NULL
and	NULL
RT-PCR	NULL
mRNAs	NULL
were	NULL
extracted	NULL
from	NULL
frozen	NULL
skin	NULL
biopsy	NULL
specimens	NULL
or	NULL
10°	NULL
control	NULL
cells	NULL
using	NULL
a	NULL
Micro-FastTrack	NULL
``	NULL
``	NULL
2.0	NULL
kit	NULL
(	NULL
Invitrogen	NULL
,	NULL
Table	NULL
1	NULL
-	NULL
Oligonucleotides	NULL
used	NULL
in	NULL
RT-PCR	NULL
for	NULL
EBV	NULL
transcripts	NULL
cDNA	NULL
Oligos	NULL
Oligonucleotide	NULL
Coordinated	NULL
in	NULL
B95.8	NULL
Annealing	NULL
temperature	NULL
Reference	NULL
sequence	NULL
(	NULL
5'-3	NULL
'	NULL
)	NULL
EBNA1	NULL
Y3	NULL
TGGCGTGTGACGTGGTGTAA	NULL
48397-48416	NULL
60°C	NULL
Brooks	NULL
et	NULL
al	NULL
,	NULL
1992	NULL
a	NULL
GTGCcGCTACCcaGaAT	NULL
@	NULL
aca	NULL
62440-62457	NULL
55°C	NULL
K	NULL
CATTTCCAGGTCCTGTACCT	NULL
107986-107967	NULL
probe	NULL
AGAGAGTAGTCTCAGGGCAT	NULL
67544-67563	NULL
EBNA2	NULL
H1	NULL
48478-48459	NULL
55°C	NULL
Oudejans	NULL
et	NULL
al	NULL
,	NULL
1995a	NULL
Y2	NULL
ATTAGAGACCACTTTGAGCC	NULL
47902-47921	NULL
probe	NULL
CTGTCCCGTATACACAGGac	NULL
54425-54406	NULL
LMP1	NULL
primer	NULL
GTGACTGGACTGGaAGGaAacc	NULL
169341-169322	NULL
62°C	NULL
Tao	NULL
et	NULL
al	NULL
,	NULL
1998	NULL
primer	NULL
GAGGGaAaTCcaTcaTa	NULL
@	NULL
aTaaTa	NULL
168718-168738	NULL
probe	NULL
AGCCCTCCTTGTCCTCTA	NULL
179325-169308	NULL
BHRF1	NULL
Y2	NULL
ATTAGAGACCACTTTGAGCC	NULL
47902-47921	NULL
55°C	NULL
Oudejans	NULL
et	NULL
al	NULL
,	NULL
1995a	NULL
H2	NULL
GTCAAGaTTTcaTcTatTaTa	NULL
53830-63849	NULL
53°C	NULL
H3	NULL
TTCTCTTGCTGCTAGCTCCA	NULL
54480-54461	NULL
probe	NULL
CTGTCCCGTATACACAGGac	NULL
54425-54406	NULL
BCRF1	NULL
primer	NULL
CGAAGGTTAGTGGTCACTCT	NULL
9681-9700	NULL
57°C	NULL
Miyazaki	NULL
et	NULL
al	NULL
,	NULL
1993	NULL
primer	NULL
CACCTGGCTTTAATTGTCATG	NULL
10186-10166	NULL
probe	NULL
TACCTGGAGGAAGTCATGCC	NULL
9921-9940	NULL
©2001	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
2001	NULL
)	NULL
84	NULL
(	NULL
7	NULL
)	NULL
,	NULL
920-925	NULL
922	NULL
Z-G	NULL
Xu	NULL
etal	NULL
Jim	NULL
``	NULL
Wuih	NULL
Figure	NULL
1	NULL
California	NULL
)	NULL
.	NULL

Reverse	NULL
transcription	NULL
was	NULL
performed	NULL
using	NULL
a	NULL
cDNA	NULL
Cycle	NULL
kit	NULL
(	NULL
Invitrogen	NULL
)	NULL
.	NULL

PCR	NULL
amplification	NULL
was	NULL
done	NULL
with	NULL
an	NULL
initial	NULL
denaturation	NULL
at	NULL
95°C	NULL
for	NULL
5	NULL
min	NULL
,	NULL
followed	NULL
by	NULL
40	NULL
cycles	NULL
consisting	NULL
of	NULL
95°C	NULL
for	NULL
1	NULL
min	NULL
,	NULL
an	NULL
optimal	NULL
annealing	NULL
temperature	NULL
for	NULL
45	NULL
s	NULL
,	NULL
72°C	NULL
for	NULL
1	NULL
min	NULL
,	NULL
and	NULL
a	NULL
final	NULL
extension	NULL
at	NULL
72°C	NULL
for	NULL
10	NULL
min	NULL
.	NULL

The	NULL
RT-PCR	NULL
products	NULL
were	NULL
transferred	NULL
to	NULL
nylon	NULL
membranes	NULL
,	NULL
and	NULL
then	NULL
hybridized	NULL
with	NULL
biotin-labelled	NULL
oligonucleotide	NULL
probes	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Xu	NULL
et	NULL
al	NULL
,	NULL
2000	NULL
)	NULL
.	NULL

Transcription	NULL
of	NULL
EBV-encoded	NULL
genes	NULL
including	NULL
the	NULL
EBNA-1	NULL
,	NULL
EBNA-2	NULL
,	NULL
LMP-1	NULL
,	NULL
BHRFI	NULL
and	NULL
BCRF1	NULL
genes	NULL
was	NULL
examined	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
the	NULL
primers	NULL
,	NULL
the	NULL
annealing	NULL
temperatures	NULL
for	NULL
PCR	NULL
amplifications	NULL
and	NULL
the	NULL
oligonucleotide	NULL
probes	NULL
for	NULL
hybridization	NULL
are	NULL
described	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

Immunostaining	NULL
In	NULL
order	NULL
to	NULL
detect	NULL
EBV	NULL
antigens	NULL
,	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
DAKO	NULL
)	NULL
to	NULL
LMP-1	NULL
(	NULL
clone	NULL
CS1-4	NULL
)	NULL
,	NULL
EBNA-2	NULL
(	NULL
clone	NULL
PE2	NULL
)	NULL
and	NULL
ZEBRA	NULL
(	NULL
clone	NULL
BZLF1	NULL
)	NULL
were	NULL
used	NULL
.	NULL

Before	NULL
incubation	NULL
with	NULL
anti-EBNA-2	NULL
or	NULL
anti-ZEBRA	NULL
antibody	NULL
,	NULL
deparaffinized	NULL
tissue	NULL
sections	NULL
were	NULL
boiled	NULL
for	NULL
5	NULL
min	NULL
in	NULL
citrate	NULL
buffer	NULL
(	NULL
0.1	NULL
mol	NULL
17	NULL
,	NULL
pH	NULL
6.0	NULL
)	NULL
.	NULL

Incubation	NULL
with	NULL
the	NULL
antibodies	NULL
was	NULL
done	NULL
at	NULL
4°C	NULL
overnight	NULL
.	NULL

For	NULL
immunophenotyping	NULL
of	NULL
the	NULL
infiltrating	NULL
cells	NULL
,	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
CD2	NULL
,	NULL
3	NULL
,	NULL
4	NULL
,	NULL
8	NULL
,	NULL
16	NULL
,	NULL
30	NULL
,	NULL
45RO	NULL
and	NULL
57	NULL
(	NULL
DAKO	NULL
)	NULL
and	NULL
CD56	NULL
(	NULL
Novocastra	NULL
)	NULL
were	NULL
used	NULL
.	NULL

The	NULL
tissue	NULL
sections	NULL
were	NULL
reacted	NULL
with	NULL
biotin-labeled	NULL
anti-mouse	NULL
immunoglobulins	NULL
,	NULL
followed	NULL
by	NULL
incubation	NULL
with	NULL
horseradish	NULL
perox-idase-labelled	NULL
streptavidin	NULL
.	NULL

Colorimetric	NULL
reaction	NULL
was	NULL
performed	NULL
by	NULL
incubation	NULL
with	NULL
a	NULL
substrate	NULL
solution	NULL
containing	NULL
diaminobenzi-dine	NULL
and	NULL
hydrogen	NULL
peroxide	NULL
.	NULL

RESULTS	NULL
Clinicopathologic	NULL
findings	NULL
The	NULL
clinical	NULL
features	NULL
of	NULL
six	NULL
patients	NULL
with	NULL
a	NULL
NK-cell	NULL
phenotype	NULL
(	NULL
NK	NULL
1-6	NULL
)	NULL
and	NULL
two	NULL
patients	NULL
with	NULL
a	NULL
T-cell	NULL
phenotype	NULL
(	NULL
Tl	NULL
and	NULL
2	NULL
)	NULL
are	NULL
summarized	NULL
in	NULL
Table	NULL
2	NULL
.	NULL

Histologically	NULL
,	NULL
tissue	NULL
necrosis	NULL
and	NULL
angiodestructive	NULL
infiltrates	NULL
were	NULL
common	NULL
in	NULL
all	NULL
patients	NULL
at	NULL
various	NULL
British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
2001	NULL
)	NULL
84	NULL
(	NULL
7	NULL
)	NULL
,	NULL
920-925	NULL
a+	NULL
Infiltrating	NULL
cells	NULL
in	NULL
the	NULL
skin	NULL
lesions	NULL
expressing	NULL
(	NULL
A	NULL
)	NULL
CD56	NULL
(	NULL
x	NULL
600	NULL
)	NULL
and	NULL
(	NULL
B	NULL
)	NULL
EBER	NULL
(	NULL
x	NULL
400	NULL
)	NULL
nees	NULL
t	NULL
__	NULL
degrees	NULL
.	NULL

All	NULL
six	NULL
patients	NULL
with	NULL
a	NULL
NK-cell	NULL
phenotype	NULL
represented	NULL
CD56	NULL
and	NULL
cytoplasmic	NULL
CD3	NULL
(	NULL
CD3	NULL
£	NULL
)	NULL
without	NULL
any	NULL
T-cell-specific	NULL
antigens	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
and	NULL
positive	NULL
signals	NULL
for	NULL
EBER	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

EBER*	NULL
cells	NULL
ranged	NULL
from	NULL
30-80	NULL
%	NULL
of	NULL
the	NULL
infiltrating	NULL
cells	NULL
.	NULL

Southern	NULL
blot	NULL
hybridization	NULL
demonstrated	NULL
non-rearranged	NULL
T-cell	NULL
receptor	NULL
genes	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
rearranged	NULL
bands	NULL
of	NULL
the	NULL
T-cell	NULL
receptor	NULL
gene	NULL
were	NULL
detected	NULL
in	NULL
two	NULL
patients	NULL
(	NULL
Tl	NULL
and	NULL
2	NULL
)	NULL
,	NULL
although	NULL
a	NULL
few	NULL
CD56*	NULL
cells	NULL
were	NULL
observed	NULL
in	NULL
case	NULL
Tl	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
confirmed	NULL
that	NULL
the	NULL
tumour	NULL
cells	NULL
in	NULL
cases	NULL
Tl	NULL
and	NULL
T2	NULL
were	NULL
of	NULL
T-cell	NULL
lineage	NULL
.	NULL

DNA	NULL
samples	NULL
from	NULL
five	NULL
patients	NULL
were	NULL
subjected	NULL
to	NULL
clonality	NULL
analyses	NULL
of	NULL
EBV	NULL
.	NULL

The	NULL
results	NULL
showed	NULL
a	NULL
single	NULL
hybridization	NULL
band	NULL
EBV	NULL
+	NULL
NK-cell	NULL
iymphoma	NULL
(	NULL
case	NULL
,	NULL
NK	NULL
1	NULL
)	NULL
TR	NULL
EVB-TR	NULL
Pt	NULL
.	NULL

B95-8	NULL
(	NULL
+	NULL
)	NULL
(	NULL
-	NULL
)	NULL
Pt	NULL
.	NULL

(	NULL
kbp	NULL
)	NULL
(	NULL
kbp	NULL
)	NULL
24.0	NULL
®	NULL
Lie	NULL
9.4	NULL
=-12.0	NULL
»	NULL
4.4	NULL
i	NULL
>	NULL
2.3	NULL
®	NULL
7.0	NULL
®	NULL
2.0	NULL
®	NULL
Figure	NULL
2	NULL
-	NULL
Clonality	NULL
analysis	NULL
of	NULL
a	NULL
representative	NULL
case	NULL
of	NULL
nasal-type	NULL
,	NULL
NK/T-cell	NULL
lymphoma	NULL
(	NULL
NK-cell	NULL
phenotype	NULL
)	NULL
.	NULL

Southern	NULL
blot	NULL
hybridization	NULL
using	NULL
a	NULL
digoxigenin-labelled	NULL
Xho-1	NULL
probe	NULL
(	NULL
Raab-Traub	NULL
and	NULL
Flynn	NULL
,	NULL
1986	NULL
)	NULL
demonstrated	NULL
a	NULL
single	NULL
band	NULL
corresponding	NULL
to	NULL
EBV	NULL
BamHI-digested	NULL
fragments	NULL
containing	NULL
the	NULL
same	NULL
number	NULL
of	NULL
EBV	NULL
terminal	NULL
repeats	NULL
(	NULL
``	NULL
right	NULL
)	NULL
and	NULL
no	NULL
rearrangement	NULL
of	NULL
TcR	NULL
B	NULL
gene	NULL
(	NULL
left	NULL
)	NULL
.	NULL

Pt	NULL
=	NULL
patient	NULL
's	NULL
sample	NULL
,	NULL
B95-8	NULL
=	NULL
an	NULL
EBV	NULL
+	NULL
cell	NULL
line	NULL
,	NULL
(	NULL
+	NULL
)	NULL
=	NULL
EBV	NULL
+	NULL
lymphoma	NULL
,	NULL
(	NULL
-	NULL
)	NULL
=	NULL
EBV-lymphoma	NULL
©2001	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
EB	NULL
virus	NULL
antigen	NULL
expression	NULL
by	NULL
NK/T-cell	NULL
lymphomas	NULL
923	NULL
Table	NULL
2	NULL
-	NULL
Patients	NULL
with	NULL
cutaneous	NULL
NK/T-cell	NULL
lymphomas	NULL
Case/age/sex	NULL
Involved	NULL
organs	NULL
Immunophenotype	NULL
TCRB	NULL
EBV-TR	NULL
Outcome	NULL
NK1/70/M	NULL
nose	NULL
,	NULL
skin	NULL
cCD3®	NULL
,	NULL
CD56	NULL
,	NULL
307	NULL
,	NULL
45RO-	NULL
,	NULL
8*	NULL
,	NULL
4	NULL
G	NULL
Clonal	NULL
Alive	NULL
NK2/63/F	NULL
nose	NULL
,	NULL
skin	NULL
,	NULL
LN	NULL
cCD3®	NULL
,	NULL
CD56	NULL
,	NULL
2+	NULL
,	NULL
57-	NULL
,	NULL
167	NULL
,	NULL
30-	NULL
G	NULL
Clonal	NULL
Dead	NULL
NK3/16/M	NULL
skin	NULL
cCD3®	NULL
,	NULL
CD56	NULL
#	NULL
,	NULL
4-	NULL
,	NULL
87	NULL
,	NULL
30-	NULL
el	NULL
ND	NULL
Dead	NULL
NK4/74/F	NULL
skin	NULL
cCD3®	NULL
,	NULL
CD56	NULL
#	NULL
,	NULL
30+	NULL
,	NULL
4	NULL
,	NULL
8~	NULL
ND	NULL
Clonal	NULL
Alive	NULL
NK5/48/F	NULL
skin	NULL
,	NULL
LN	NULL
cCD3®	NULL
,	NULL
CD56	NULL
,	NULL
45R0	NULL
,	NULL
87	NULL
,	NULL
4-	NULL
el	NULL
Clonal	NULL
Alive	NULL
NK6/80/M	NULL
skin	NULL
cCD3®	NULL
,	NULL
CD56	NULL
#	NULL
,	NULL
4-	NULL
,	NULL
87	NULL
,	NULL
30-	NULL
el	NULL
ND	NULL
Dead	NULL
T1/64/F	NULL
skin	NULL
,	NULL
LN	NULL
cCD3®	NULL
,	NULL
CD56	NULL
,	NULL
3	NULL
,	NULL
4+	NULL
,	NULL
8+	NULL
,	NULL
45RO®	NULL
R	NULL
Clonal	NULL
Dead	NULL
``	NULL
T2/36/F	NULL
skin	NULL
cCD3®	NULL
,	NULL
CD56-	NULL
,	NULL
45R0¢	NULL
R	NULL
ND	NULL
Dead	NULL
NK	NULL
=	NULL
NK-cell	NULL
lymphomas	NULL
,	NULL
T	NULL
=	NULL
T-cell	NULL
lymphomas	NULL
,	NULL
LN	NULL
=	NULL
lymph	NULL
node	NULL
,	NULL
TCR	NULL
=	NULL
T-cell	NULL
receptor	NULL
,	NULL
EBV-TR	NULL
=	NULL
EBV	NULL
terminal	NULL
repeats	NULL
,	NULL
+	NULL
=	NULL
positive	NULL
,	NULL
G	NULL
=	NULL
germ	NULL
,	NULL
R	NULL
=	NULL
rearranged	NULL
,	NULL
ND	NULL
=	NULL
not	NULL
done	NULL
.	NULL

``	NULL
The	NULL
cause	NULL
of	NULL
death	NULL
was	NULL
unrelated	NULL
to	NULL
lymphoma	NULL
.	NULL

Table	NULL
3	NULL
-	NULL
The	NULL
expression	NULL
patterns	NULL
of	NULL
EBV-encoded	NULL
genes	NULL
by	NULL
NK/T-cell	NULL
lymphomas	NULL
Cases	NULL
EBER	NULL
by	NULL
ISH	NULL
EBV	NULL
gene	NULL
expression	NULL
determined	NULL
by	NULL
RT-PCR	NULL
EBV	NULL
antigen	NULL
expression	NULL
by	NULL
immunostaining	NULL
EBNA1	NULL
EBNA2	NULL
LMP-1	NULL
BHRF1	NULL
BCRF1	NULL
LMP-1	NULL
EBNA	NULL
ZEBRA	NULL
YUK	NULL
QUK	NULL
Y2/H3	NULL
H2/H3	NULL
-	NULL
(	NULL
vIL-10	NULL
)	NULL
NK1	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
NK2	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
+	NULL
-	NULL
+	NULL
-	NULL
-	NULL
NK3	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
-	NULL
+/-	NULL
-	NULL
-	NULL
NK4	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
NKS5	NULL
+	NULL
-	NULL
+/-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
ND	NULL
ND	NULL
NK6	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
-	NULL
-	NULL
ND	NULL
ND	NULL
ND	NULL
T1	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
T2	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
Molt	NULL
ND	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
B95.8	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
Raji	NULL
ND	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
Jiyoye	NULL
ND	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+/-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
EBER	NULL
=	NULL
EBV-encoded	NULL
small	NULL
nuclear	NULL
RNA	NULL
,	NULL
ISH	NULL
=	NULL
in	NULL
situ	NULL
hybridization	NULL
,	NULL
+	NULL
=	NULL
positive	NULL
;	NULL
+/-	NULL
=	NULL
weakly	NULL
positive	NULL
,	NULL
-=	NULL
negative	NULL
,	NULL
ND	NULL
=	NULL
not	NULL
done	NULL
.	NULL

with	NULL
a	NULL
Xho-1	NULL
probe	NULL
,	NULL
indicating	NULL
clonal	NULL
proliferation	NULL
of	NULL
the	NULL
neoplastic	NULL
cells	NULL
infected	NULL
with	NULL
EBV	NULL
containing	NULL
the	NULL
same	NULL
number	NULL
of	NULL
terminal	NULL
repeats	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

Four	NULL
years	NULL
after	NULL
onset	NULL
,	NULL
four	NULL
patients	NULL
(	NULL
NK2	NULL
,	NULL
3	NULL
,	NULL
6	NULL
and	NULL
T2	NULL
)	NULL
had	NULL
died	NULL
because	NULL
of	NULL
progressive	NULL
illness	NULL
,	NULL
and	NULL
one	NULL
patient	NULL
(	NULL
Tl	NULL
)	NULL
died	NULL
of	NULL
a	NULL
&	NULL
o	NULL
A	NULL
t	NULL
0	NULL
(	NULL
r	NULL
&	NULL
6	NULL
a	NULL
.o	NULL
SEE	NULL
aq	NULL
U	NULL
K	NULL
EBNA1	NULL
W	NULL
(	NULL
o	NULL
%	NULL
)	NULL
236	NULL
bp	NULL
5	NULL
3	NULL
X	NULL
va	NULL
U	NULL
ok	NULL
EBNA1	NULL
d	NULL
(	NULL
yak	NULL
)	NULL
265	NULL
bp	NULL
5	NULL
3	NULL
EBNA1	NULL
EBNA2	NULL
-	NULL
>	NULL
v2	NULL
Hs	NULL
BHRF	NULL
5	NULL
e	NULL
``	NULL
latent	NULL
C	NULL
S	NULL
lis	NULL
5-3	NULL
(	NULL
vas	NULL
)	NULL
[	NULL
-	NULL
>	NULL
‘	NULL
9	NULL
‘	NULL
243	NULL
bp	NULL
H2	NULL
-	NULL
He	NULL
®	NULL
lytic	NULL
as	NULL
BHRF	NULL
k	NULL
mieten	NULL
(	NULL
Hake	NULL
)	NULL
3	NULL
§	NULL
25	NULL
%	NULL
BHRF1	NULL
sori	NULL
-	NULL
W	NULL
Slig	NULL
.	NULL

x*	NULL
(	NULL
Me	NULL
)	NULL
(	NULL
ewe	NULL
-~	NULL
Figure	NULL
3	NULL
-	NULL
Transcripts	NULL
of	NULL
EBV	NULL
genes	NULL
in	NULL
NK/T-cell	NULL
lymphoma	NULL
.	NULL

Schematic	NULL
drawings	NULL
indicate	NULL
the	NULL
complementary	NULL
sites	NULL
of	NULL
the	NULL
primer	NULL
sets	NULL
.	NULL

The	NULL
Q/U/K-spliced	NULL
EBNA-1	NULL
and	NULL
LMP-1	NULL
transcripts	NULL
are	NULL
detected	NULL
in	NULL
all	NULL
EBV*NK/T-cell	NULL
lymphomas	NULL
,	NULL
but	NULL
neither	NULL
Y3/U/K-spliced	NULL
EBNA-1	NULL
nor	NULL
EBNA-2	NULL
transcript	NULL
is	NULL
negative	NULL
.	NULL

Among	NULL
the	NULL
patients	NULL
'	NULL
samples	NULL
,	NULL
the	NULL
latent	NULL
Y2/H3	NULL
(	NULL
HF	NULL
)	NULL
-spliced	NULL
BHRF1	NULL
transcript	NULL
is	NULL
positive	NULL
in	NULL
one	NULL
case	NULL
(	NULL
NK2	NULL
)	NULL
,	NULL
and	NULL
the	NULL
BCRF1	NULL
transcript	NULL
is	NULL
present	NULL
in	NULL
two	NULL
cases	NULL
(	NULL
NK2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

NK	NULL
=	NULL
NK-cell	NULL
lymphoma	NULL
,	NULL
T	NULL
=	NULL
T-cell	NULL
lymphoma	NULL
©2001	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
complication	NULL
unrelated	NULL
to	NULL
lymphoma	NULL
.	NULL

Among	NULL
them	NULL
,	NULL
a	NULL
patient	NULL
with	NULL
NK-cell	NULL
phenotype	NULL
(	NULL
NK2	NULL
)	NULL
had	NULL
the	NULL
most	NULL
aggressive	NULL
course	NULL
,	NULL
and	NULL
died	NULL
6	NULL
months	NULL
after	NULL
onset	NULL
.	NULL

Expression	NULL
pattern	NULL
of	NULL
latency-associated	NULL
EBV	NULL
genes	NULL
In	NULL
order	NULL
to	NULL
determine	NULL
the	NULL
latency	NULL
pattern	NULL
of	NULL
EBV	NULL
infection	NULL
in	NULL
our	NULL
patients	NULL
,	NULL
we	NULL
analysed	NULL
the	NULL
transcripts	NULL
of	NULL
the	NULL
EBNA-1	NULL
,	NULL
EBNA-2	NULL
and	NULL
LMP-1	NULL
genes	NULL
by	NULL
RT-PCR	NULL
.	NULL

The	NULL
EBNA-1	NULL
mRNA	NULL
was	NULL
found	NULL
in	NULL
all	NULL
patients	NULL
and	NULL
EBV-positive	NULL
cell	NULL
lines	NULL
such	NULL
as	NULL
B95.8	NULL
,	NULL
Raji	NULL
and	NULL
Jiyoye	NULL
,	NULL
whereas	NULL
the	NULL
EBNA-2	NULL
mRNA	NULL
was	NULL
absent	NULL
in	NULL
our	NULL
patients	NULL
but	NULL
was	NULL
present	NULL
in	NULL
the	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
EBNA-1	NULL
promoters	NULL
used	NULL
to	NULL
drive	NULL
transcription	NULL
were	NULL
different	NULL
between	NULL
the	NULL
patients	NULL
and	NULL
the	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
Cp/Wp	NULL
,	NULL
which	NULL
generates	NULL
a	NULL
Y/U/K-spliced	NULL
form	NULL
,	NULL
was	NULL
only	NULL
used	NULL
by	NULL
cell	NULL
lines	NULL
(	NULL
Table	NULL
3	NULL
,	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
a	NULL
downstream	NULL
promoter	NULL
,	NULL
Qp	NULL
,	NULL
which	NULL
produces	NULL
a	NULL
Q/U/K	NULL
initiated	NULL
transcript	NULL
,	NULL
was	NULL
used	NULL
in	NULL
both	NULL
the	NULL
cell	NULL
lines	NULL
and	NULL
our	NULL
patients	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
EBNA-1	NULL
transcript	NULL
was	NULL
driven	NULL
from	NULL
the	NULL
Qp	NULL
in	NULL
NK/T-cell	NULL
lymphomas	NULL
without	NULL
usage	NULL
of	NULL
the	NULL
Cp/Wp	NULL
.	NULL

The	NULL
LMP-1	NULL
mRNA	NULL
was	NULL
detected	NULL
in	NULL
seven	NULL
of	NULL
eight	NULL
patients	NULL
and	NULL
the	NULL
EBV-positive	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
BHRF1	NULL
gene	NULL
,	NULL
which	NULL
has	NULL
partial	NULL
sequence	NULL
homology	NULL
to	NULL
the	NULL
human	NULL
bel-2	NULL
proto-oncogene	NULL
,	NULL
was	NULL
studied	NULL
using	NULL
two	NULL
different	NULL
primer	NULL
sets	NULL
,	NULL
Y2/H3	NULL
and	NULL
H2/H3	NULL
for	NULL
detection	NULL
of	NULL
possible	NULL
latent	NULL
(	NULL
Y2/HF-spliced	NULL
)	NULL
and	NULL
lytic	NULL
(	NULL
H2/HF-spliced	NULL
)	NULL
tran-scripts	NULL
,	NULL
respectively	NULL
(	NULL
Oudejans	NULL
et	NULL
al	NULL
,	NULL
1995b	NULL
)	NULL
.	NULL

Both	NULL
latent	NULL
Y2/HF-and	NULL
lytic	NULL
H2/HP-spliced	NULL
transcripts	NULL
of	NULL
the	NULL
BHRF1	NULL
gene	NULL
were	NULL
detected	NULL
in	NULL
the	NULL
EBV-positive	NULL
cell	NULL
lines	NULL
,	NULL
whereas	NULL
only	NULL
the	NULL
latent	NULL
British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
2001	NULL
)	NULL
84	NULL
(	NULL
7	NULL
)	NULL
,	NULL
920-925	NULL
924	NULL
Z-G	NULL
Xu	NULL
etal	NULL
se	NULL
<	NULL
>	NULL
``	NULL
3	NULL
,	NULL
<	NULL
a	NULL
ja	NULL
.	NULL

*	NULL
a	NULL
Z.	NULL
z	NULL
7	NULL
``	NULL
l..-	NULL
O	NULL
b	NULL
“	NULL
is	NULL
.	NULL

kn	NULL
Figure	NULL
4	NULL
-	NULL
Immunostaining	NULL
of	NULL
the	NULL
LMP-1	NULL
and	NULL
ZEBRA	NULL
antigens	NULL
in	NULL
paraffin-embedded	NULL
tissue	NULL
and	NULL
cell	NULL
preparations	NULL
from	NULL
NK/T-cell	NULL
lymphomas	NULL
and	NULL
an	NULL
EBV*	NULL
lymphoblastic	NULL
cell	NULL
line	NULL
,	NULL
B95.8	NULL
,	NULL
respectively	NULL
.	NULL

Neither	NULL
(	NULL
A	NULL
)	NULL
LMP-1	NULL
nor	NULL
(	NULL
C	NULL
)	NULL
ZEBRA	NULL
is	NULL
present	NULL
in	NULL
the	NULL
NKW/T	NULL
cell	NULL
lymphoma	NULL
,	NULL
but	NULL
both	NULL
antigens	NULL
(	NULL
B	NULL
and	NULL
D	NULL
,	NULL
respectively	NULL
)	NULL
are	NULL
positive	NULL
in	NULL
B95.8	NULL
Y2/HP-spliced	NULL
transcript	NULL
was	NULL
detected	NULL
in	NULL
one	NULL
(	NULL
NK2	NULL
)	NULL
of	NULL
eight	NULL
patients	NULL
with	NULL
NK/T-cell	NULL
lymphoma	NULL
.	NULL

The	NULL
BCRF1	NULL
gene	NULL
,	NULL
which	NULL
encodes	NULL
viral	NULL
IL-10	NULL
,	NULL
was	NULL
transcribed	NULL
in	NULL
all	NULL
EBV-positive	NULL
cell	NULL
lines	NULL
and	NULL
two	NULL
patients	NULL
(	NULL
NK2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

The	NULL
patient	NULL
,	NULL
NK2	NULL
,	NULL
who	NULL
died	NULL
of	NULL
the	NULL
most	NULL
aggressive	NULL
course	NULL
of	NULL
the	NULL
illness	NULL
,	NULL
expressed	NULL
both	NULL
the	NULL
BHRF1	NULL
(	NULL
bel-2	NULL
homologue	NULL
)	NULL
and	NULL
BCRFI1	NULL
(	NULL
viral	NULL
IL-10	NULL
)	NULL
transcripts	NULL
.	NULL

EBV	NULL
antigen	NULL
expression	NULL
The	NULL
EBNA-2	NULL
and	NULL
ZEBRA	NULL
,	NULL
an	NULL
'immediate-early	NULL
'	NULL
transcriptional	NULL
act-ivator	NULL
was	NULL
detected	NULL
in	NULL
the	NULL
paraffin-embedded	NULL
cell	NULL
pellets	NULL
of	NULL
B95.8	NULL
,	NULL
Raji	NULL
and	NULL
Jiyoye	NULL
cells	NULL
,	NULL
although	NULL
the	NULL
percentages	NULL
of	NULL
the	NULL
positive	NULL
cells	NULL
varied	NULL
in	NULL
the	NULL
cell	NULL
lines	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

Neither	NULL
EBNA-2-	NULL
nor	NULL
ZEBRA-positive	NULL
cells	NULL
were	NULL
detected	NULL
in	NULL
the	NULL
lesional	NULL
tissue	NULL
sections	NULL
from	NULL
our	NULL
patients	NULL
.	NULL

With	NULL
paraffin-embedded	NULL
tissue	NULL
sections	NULL
,	NULL
LMP-1	NULL
antigens	NULL
were	NULL
strongly	NULL
expressed	NULL
by	NULL
the	NULL
EBV-positive	NULL
cell	NULL
lines	NULL
,	NULL
but	NULL
no	NULL
LMP-1	NULL
antigens	NULL
were	NULL
detected	NULL
in	NULL
the	NULL
biopsy	NULL
specimens	NULL
from	NULL
the	NULL
patients	NULL
.	NULL

DISCUSSION	NULL
Our	NULL
study	NULL
demonstrats	NULL
that	NULL
in	NULL
addition	NULL
to	NULL
EBER	NULL
,	NULL
both	NULL
the	NULL
EBNA-1	NULL
and	NULL
LMP-1	NULL
genes	NULL
are	NULL
transcribed	NULL
in	NULL
vivo	NULL
in	NULL
patients	NULL
with	NULL
EBV-associated	NULL
NK/T-cell	NULL
lymphomas	NULL
,	NULL
without	NULL
any	NULL
EBNA-2	NULL
gene	NULL
transcript	NULL
.	NULL

This	NULL
finding	NULL
was	NULL
further	NULL
confirmed	NULL
by	NULL
the	NULL
usage	NULL
of	NULL
promoters	NULL
for	NULL
the	NULL
EBNA-1	NULL
gene	NULL
in	NULL
the	NULL
patients	NULL
:	NULL
the	NULL
Qp	NULL
promoter	NULL
was	NULL
used	NULL
in	NULL
the	NULL
NK/T-cell	NULL
lymphomas	NULL
,	NULL
and	NULL
both	NULL
the	NULL
Qp	NULL
and	NULL
Cp/Wp	NULL
were	NULL
used	NULL
in	NULL
the	NULL
EBV-positive	NULL
cell	NULL
lines	NULL
.	NULL

When	NULL
the	NULL
Qp	NULL
promoter	NULL
is	NULL
used	NULL
,	NULL
the	NULL
Q/U/K-spliced	NULL
EBNA-1	NULL
mRNA	NULL
is	NULL
generated	NULL
,	NULL
but	NULL
the	NULL
other	NULL
latent	NULL
genes	NULL
,	NULL
such	NULL
as	NULL
EBNA-2	NULL
and	NULL
EBNA-3	NULL
,	NULL
can	NULL
not	NULL
be	NULL
transcribed	NULL
because	NULL
the	NULL
Cp/Wp	NULL
promoters	NULL
are	NULL
silent	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
nasal-type	NULL
,	NULL
extranodal	NULL
NK/T-cell	NULL
lymphomas	NULL
expressed	NULL
viral	NULL
antigens	NULL
of	NULL
EBNA-1	NULL
and	NULL
LMP-1	NULL
in	NULL
the	NULL
latency	NULL
II	NULL
pattern	NULL
.	NULL

Unlike	NULL
the	NULL
latency	NULL
III	NULL
pattern	NULL
observed	NULL
in	NULL
EBV-related	NULL
lymphoproliferative	NULL
disorders	NULL
in	NULL
patients	NULL
with	NULL
immunodeficiency	NULL
(	NULL
Hamilton-Dutoit	NULL
et	NULL
al	NULL
,	NULL
1993	NULL
)	NULL
,	NULL
NK/T-cell	NULL
lymphomas	NULL
may	NULL
minimize	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
latency-associated	NULL
viral	NULL
antigens	NULL
which	NULL
might	NULL
be	NULL
targeted	NULL
by	NULL
host	NULL
immune	NULL
system	NULL
.	NULL

British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
2001	NULL
)	NULL
84	NULL
(	NULL
7	NULL
)	NULL
,	NULL
920-925	NULL
EBNA-1	NULL
is	NULL
constantly	NULL
expressed	NULL
by	NULL
EBV-infected	NULL
cells	NULL
in	NULL
any	NULL
latency	NULL
pattern	NULL
,	NULL
but	NULL
the	NULL
host	NULL
's	NULL
immune	NULL
response	NULL
never	NULL
occurs	NULL
against	NULL
the	NULL
molecules	NULL
(	NULL
Levitskaya	NULL
et	NULL
al	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

LMP-1	NULL
acts	NULL
as	NULL
a	NULL
direct	NULL
oncogene	NULL
to	NULL
transform	NULL
epithelial	NULL
cells	NULL
morphologically	NULL
(	NULL
Fahraeus	NULL
et	NULL
al	NULL
,	NULL
1990	NULL
)	NULL
and	NULL
prevent	NULL
B-lymphoma	NULL
cells	NULL
from	NULL
undergoing	NULL
apoptosis	NULL
by	NULL
up-regulating	NULL
the	NULL
expression	NULL
of	NULL
cellular	NULL
bel-2	NULL
(	NULL
Henderson	NULL
et	NULL
al	NULL
,	NULL
1991	NULL
)	NULL
.	NULL

We	NULL
could	NULL
not	NULL
detect	NULL
LMP-1	NULL
antigens	NULL
by	NULL
immunostaining	NULL
despite	NULL
the	NULL
presence	NULL
of	NULL
LMP-1	NULL
gene	NULL
transcripts	NULL
by	NULL
RT-PCR	NULL
.	NULL

This	NULL
discrepancy	NULL
may	NULL
be	NULL
because	NULL
RT-PCR	NULL
is	NULL
more	NULL
sensitive	NULL
than	NULL
immunostaining	NULL
using	NULL
paraffin-embedded	NULL
tissue	NULL
sections	NULL
.	NULL

The	NULL
EBV	NULL
BHRFI	NULL
gene	NULL
encodes	NULL
a	NULL
protein	NULL
which	NULL
has	NULL
sequence	NULL
homology	NULL
to	NULL
cellular	NULL
bel-2	NULL
,	NULL
and	NULL
this	NULL
viral	NULL
bel-2	NULL
homologue	NULL
protects	NULL
cells	NULL
from	NULL
apoptosis	NULL
(	NULL
Henderson	NULL
et	NULL
al	NULL
,	NULL
1993	NULL
)	NULL
.	NULL

High	NULL
levels	NULL
of	NULL
the	NULL
BHRFI	NULL
transcript	NULL
are	NULL
expressed	NULL
in	NULL
the	NULL
lytic	NULL
cycle	NULL
,	NULL
but	NULL
differently	NULL
spliced	NULL
BHRF1	NULL
transcript	NULL
was	NULL
found	NULL
during	NULL
latency	NULL
,	NULL
although	NULL
at	NULL
much	NULL
lower	NULL
levels	NULL
(	NULL
Oudejans	NULL
et	NULL
al	NULL
,	NULL
1995b	NULL
)	NULL
.	NULL

In	NULL
our	NULL
series	NULL
,	NULL
the	NULL
latent	NULL
(	NULL
Y2/HPF-spliced	NULL
)	NULL
transcript	NULL
was	NULL
present	NULL
in	NULL
one	NULL
case	NULL
(	NULL
NK2	NULL
)	NULL
,	NULL
whereas	NULL
no	NULL
lytic	NULL
(	NULL
H2/HP-spliced	NULL
)	NULL
transcript	NULL
was	NULL
detected	NULL
in	NULL
the	NULL
patients	NULL
'	NULL
samples	NULL
.	NULL

The	NULL
BCRF1	NULL
gene	NULL
encodes	NULL
viral	NULL
IL-10	NULL
which	NULL
has	NULL
more	NULL
than	NULL
70	NULL
%	NULL
amino	NULL
acid	NULL
identity	NULL
with	NULL
human	NULL
IL-10	NULL
(	NULL
Moore	NULL
et	NULL
al	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

Human	NULL
and	NULL
viral	NULL
IL-10	NULL
share	NULL
several	NULL
biological	NULL
functions	NULL
such	NULL
as	NULL
inhibition	NULL
of	NULL
interferon-y	NULL
secretion	NULL
and	NULL
suppression	NULL
of	NULL
T-cell	NULL
proliferation	NULL
(	NULL
Hsu	NULL
et	NULL
al	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
postulated	NULL
that	NULL
the	NULL
production	NULL
of	NULL
human	NULL
IL-10	NULL
correlates	NULL
with	NULL
poor	NULL
prognosis	NULL
in	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
(	NULL
Blay	NULL
et	NULL
al	NULL
,	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
our	NULL
series	NULL
,	NULL
the	NULL
BCRFI1	NULL
gene	NULL
was	NULL
transcribed	NULL
in	NULL
two	NULL
patients	NULL
with	NULL
cutaneous	NULL
NK-cell	NULL
lymphomas	NULL
(	NULL
NK2	NULL
and	NULL
3	NULL
)	NULL
who	NULL
died	NULL
after	NULL
two	NULL
years	NULL
because	NULL
of	NULL
progression	NULL
of	NULL
the	NULL
illness	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
a	NULL
patient	NULL
,	NULL
NK2	NULL
,	NULL
with	NULL
simultaneous	NULL
expression	NULL
of	NULL
both	NULL
viral	NULL
IL-10	NULL
and	NULL
viral	NULL
bel-2	NULL
homologue	NULL
,	NULL
did	NULL
have	NULL
an	NULL
aggressive	NULL
clinical	NULL
course	NULL
.	NULL

The	NULL
BCRF1	NULL
gene	NULL
encoding	NULL
viral	NULL
IL-10	NULL
was	NULL
thought	NULL
to	NULL
be	NULL
transcribed	NULL
only	NULL
during	NULL
a	NULL
lytic	NULL
phase	NULL
of	NULL
EBV	NULL
replication	NULL
(	NULL
Hudson	NULL
et	NULL
al	NULL
,	NULL
1985	NULL
)	NULL
,	NULL
but	NULL
was	NULL
recently	NULL
found	NULL
to	NULL
be	NULL
expressed	NULL
very	NULL
early	NULL
during	NULL
B-cell	NULL
infection	NULL
(	NULL
Miyazaki	NULL
et	NULL
al	NULL
,	NULL
1993	NULL
;	NULL
Zeidler	NULL
et	NULL
al	NULL
,	NULL
1997	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
mechanism	NULL
of	NULL
the	NULL
BCRF1	NULL
gene	NULL
expression	NULL
has	NULL
been	NULL
a	NULL
controversial	NULL
issue	NULL
,	NULL
we	NULL
could	NULL
not	NULL
rule	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
a	NULL
small	NULL
number	NULL
of	NULL
the	NULL
neoplastic	NULL
cells	NULL
changed	NULL
from	NULL
the	NULL
latent	NULL
to	NULL
the	NULL
©2001	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
lytic	NULL
cycle	NULL
(	NULL
Miller	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
bystander	NULL
or	NULL
reactive	NULL
cells	NULL
with	NULL
lytic	NULL
EBV	NULL
infection	NULL
might	NULL
coexist	NULL
in	NULL
the	NULL
lesions	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
the	NULL
latency	NULL
II	NULL
pattern	NULL
of	NULL
viral	NULL
gene	NULL
transcripts	NULL
in	NULL
the	NULL
nasal-type	NULL
,	NULL
NK/T	NULL
cell	NULL
lymphomas	NULL
(	NULL
EBER*	NULL
,	NULL
EBNA1*	NULL
,	NULL
LMP-1*	NULL
,	NULL
EBNAZ~	NULL
)	NULL
is	NULL
distinct	NULL
from	NULL
that	NULL
identified	NULL
in	NULL
B-cell	NULL
system	NULL
,	NULL
and	NULL
consistent	NULL
with	NULL
that	NULL
identified	NULL
in	NULL
nasopharyngeal	NULL
carcinomas	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
viral	NULL
IL-10	NULL
and	NULL
bel-2	NULL
homologue	NULL
might	NULL
be	NULL
responsible	NULL
for	NULL
tumour	NULL
progression	NULL
by	NULL
interference	NULL
with	NULL
the	NULL
host	NULL
immune	NULL
system	NULL
and	NULL
apoptosis	NULL
,	NULL
respectively	NULL
.	NULL

ACKNOWLEDGEMENTS	NULL
This	NULL
study	NULL
was	NULL
supported	NULL
by	NULL
Grant-in-Aid	NULL
for	NULL
Scientific	NULL
Research	NULL
(	NULL
C	NULL
)	NULL
(	NULL
11670843	NULL
)	NULL
and	NULL
Grant-in-Aid	NULL
for	NULL
Scientific	NULL
Research	NULL
on	NULL
Priority	NULL
Areas	NULL
(	NULL
C	NULL
)	NULL
(	NULL
12218235	NULL
)	NULL
from	NULL
the	NULL
Ministry	NULL
of	NULL
Education	NULL
,	NULL
Science	NULL
,	NULL
Sports	NULL
and	NULL
Culture	NULL
in	NULL
Japan	NULL
.	NULL

REFERENCES	NULL
Blay	NULL
JY	NULL
,	NULL
Burdin	NULL
N	NULL
,	NULL
Rousset	NULL
F	NULL
,	NULL
Lenoir	NULL
G	NULL
,	NULL
Biron	NULL
P	NULL
,	NULL
Philip	NULL
T	NULL
,	NULL
Banchereau	NULL
J	NULL
and	NULL
Favrot	NULL
MC	NULL
(	NULL
1993	NULL
)	NULL
Serum	NULL
interleukin-10	NULL
in	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
:	NULL
a	NULL
prognostic	NULL
factor	NULL
.	NULL

Blood	NULL
82	NULL
:	NULL
2169-2174	NULL
Brooks	NULL
L	NULL
,	NULL
Yao	NULL
QY	NULL
,	NULL
Rickinson	NULL
AB	NULL
and	NULL
Young	NULL
LS	NULL
(	NULL
1992	NULL
)	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
gene	NULL
transcription	NULL
in	NULL
nasopharyngeal	NULL
carcinoma	NULL
cells	NULL
:	NULL
coexpression	NULL
of	NULL
EBNA1	NULL
,	NULL
LMP1	NULL
,	NULL
and	NULL
LMP2	NULL
transcripts	NULL
.	NULL

J	NULL
Virol	NULL
66	NULL
:	NULL
2689-2697	NULL
Chan	NULL
JKC	NULL
,	NULL
Sin	NULL
VC	NULL
,	NULL
Wong	NULL
KF	NULL
,	NULL
Ng	NULL
CS	NULL
,	NULL
Tsang	NULL
YW	NULL
,	NULL
Chan	NULL
CH	NULL
,	NULL
Cheung	NULL
MMMC	NULL
and	NULL
Lau	NULL
WH	NULL
(	NULL
1997	NULL
)	NULL
Nonnasal	NULL
lymphoma	NULL
expressing	NULL
the	NULL
natural	NULL
killer	NULL
cell	NULL
marker	NULL
CD56	NULL
:	NULL
a	NULL
clinicopathologic	NULL
study	NULL
of	NULL
49	NULL
cases	NULL
of	NULL
uncommon	NULL
aggressive	NULL
neoplasm	NULL
.	NULL

Blood	NULL
89	NULL
:	NULL
4501-4513	NULL
Cohen	NULL
JL	NULL
and	NULL
Lekstrom	NULL
K	NULL
(	NULL
1999	NULL
)	NULL
Epstein-Barr	NULL
virus	NULL
BARF1	NULL
protein	NULL
is	NULL
dispensable	NULL
for	NULL
B-cell	NULL
transformation	NULL
and	NULL
inhibits	NULL
alpha	NULL
interferon	NULL
secretion	NULL
from	NULL
mononuclear	NULL
cells	NULL
.	NULL

J	NULL
Virol	NULL
73	NULL
:	NULL
7627-7632	NULL
Deacon	NULL
EM	NULL
,	NULL
Pallesen	NULL
G	NULL
,	NULL
Niedobitek	NULL
G	NULL
,	NULL
Crocker	NULL
J	NULL
,	NULL
Brooks	NULL
L	NULL
,	NULL
Rickinson	NULL
AB	NULL
and	NULL
Young	NULL
LS	NULL
(	NULL
1993	NULL
)	NULL
Epstein-Barr	NULL
virus	NULL
and	NULL
Hodgkin	NULL
's	NULL
disease	NULL
:	NULL
transcriptional	NULL
analysis	NULL
of	NULL
virus	NULL
latency	NULL
in	NULL
the	NULL
malignant	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
177	NULL
:	NULL
339-349	NULL
Fahracus	NULL
R	NULL
,	NULL
Rumo	NULL
L	NULL
,	NULL
Rhim	NULL
JS	NULL
and	NULL
Klein	NULL
G	NULL
(	NULL
1990	NULL
)	NULL
Morphological	NULL
transformation	NULL
of	NULL
human	NULL
keratinocytes	NULL
expressing	NULL
the	NULL
LMP	NULL
gene	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Nature	NULL
345	NULL
:	NULL
447-449	NULL
Hamilton-Dutoit	NULL
SJ	NULL
,	NULL
Rea	NULL
D	NULL
,	NULL
Raphael	NULL
M	NULL
,	NULL
Sandvej	NULL
K	NULL
,	NULL
Delecluse	NULL
HJ	NULL
,	NULL
Gisselbrecht	NULL
C	NULL
,	NULL
Marelle	NULL
L	NULL
,	NULL
van	NULL
Krieken	NULL
HJ	NULL
and	NULL
Pallesen	NULL
G	NULL
(	NULL
1993	NULL
)	NULL
Epstein-Barr	NULL
virus-latent	NULL
gene	NULL
expression	NULL
and	NULL
tumour	NULL
cell	NULL
phenotype	NULL
in	NULL
acquired	NULL
immunodeficiency	NULL
syndrome-related	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
.	NULL

Correlation	NULL
of	NULL
lymphoma	NULL
phenotype	NULL
with	NULL
three	NULL
distinct	NULL
patterns	NULL
of	NULL
viral	NULL
latency	NULL
.	NULL

Am	NULL
J	NULL
Pathol	NULL
143	NULL
:	NULL
1072-1085	NULL
Harabuchi	NULL
Y	NULL
,	NULL
Yamanaka	NULL
N	NULL
,	NULL
Kataura	NULL
A	NULL
,	NULL
Imai	NULL
S	NULL
,	NULL
Kinoshita	NULL
T	NULL
,	NULL
Mizuno	NULL
F	NULL
and	NULL
Osato	NULL
T	NULL
(	NULL
1990	NULL
)	NULL
Epstein-Barr	NULL
virus	NULL
in	NULL
nasal	NULL
T-cell	NULL
lymphomas	NULL
in	NULL
patients	NULL
with	NULL
lethal	NULL
midline	NULL
granuloma	NULL
.	NULL

Lancet	NULL
335	NULL
:	NULL
128-130	NULL
Harris	NULL
NL	NULL
,	NULL
Jaffe	NULL
ES	NULL
,	NULL
Diebold	NULL
J	NULL
,	NULL
Flandrin	NULL
G	NULL
,	NULL
Muller-Hermelink	NULL
K	NULL
,	NULL
Vardiman	NULL
J	NULL
,	NULL
Lister	NULL
TA	NULL
and	NULL
Bloomfield	NULL
CD	NULL
(	NULL
1999	NULL
)	NULL
World	NULL
Health	NULL
Organization	NULL
Classification	NULL
of	NULL
neoplastic	NULL
diseases	NULL
of	NULL
the	NULL
hematopoietic	NULL
and	NULL
lymphoid	NULL
tissues	NULL
:	NULL
Report	NULL
of	NULL
the	NULL
Clinical	NULL
Advisory	NULL
Committee	NULL
Meeting	NULL
-	NULL
Airlie	NULL
House	NULL
,	NULL
Virginia	NULL
,	NULL
November	NULL
1997	NULL
.	NULL

J	NULL
Clin	NULL
Oncol	NULL
17	NULL
:	NULL
3835-3849	NULL
Henderson	NULL
S	NULL
,	NULL
Rowe	NULL
M	NULL
,	NULL
Gregory	NULL
C	NULL
,	NULL
Croom-Carter	NULL
D	NULL
,	NULL
Wang	NULL
F	NULL
,	NULL
Longnecker	NULL
R	NULL
,	NULL
Kieff	NULL
E	NULL
and	NULL
Rickinson	NULL
A	NULL
(	NULL
1991	NULL
)	NULL
Induction	NULL
of	NULL
bel-2	NULL
expression	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
membrane	NULL
protein	NULL
1	NULL
protects	NULL
infected	NULL
B	NULL
cells	NULL
from	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
65	NULL
:	NULL
1107-1115	NULL
Henderson	NULL
S	NULL
,	NULL
Huen	NULL
D	NULL
,	NULL
Rowe	NULL
M	NULL
,	NULL
Dawson	NULL
C	NULL
,	NULL
Johnson	NULL
G	NULL
and	NULL
Rickinson	NULL
A	NULL
(	NULL
1993	NULL
)	NULL
Epstein-Barr	NULL
virus-coded	NULL
BHRF1	NULL
protein	NULL
,	NULL
a	NULL
viral	NULL
homologue	NULL
of	NULL
Bel-2	NULL
,	NULL
protects	NULL
human	NULL
B	NULL
cells	NULL
from	NULL
programmed	NULL
cell	NULL
death	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Acad	NULL
Sci	NULL
USA	NULL
90	NULL
:	NULL
8479-8483	NULL
Hsu	NULL
DH	NULL
,	NULL
Malefyt	NULL
RDW	NULL
,	NULL
Fiorentino	NULL
DF	NULL
,	NULL
Dang	NULL
MN	NULL
,	NULL
Vieira	NULL
P	NULL
,	NULL
deVries	NULL
J	NULL
,	NULL
Spits	NULL
H	NULL
,	NULL
Mosmann	NULL
TR	NULL
and	NULL
Moore	NULL
KW	NULL
(	NULL
1990	NULL
)	NULL
Expression	NULL
of	NULL
Interleukin-10	NULL
activity	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
protein	NULL
BCRF1	NULL
.	NULL

Science	NULL
250	NULL
:	NULL
830-832	NULL
Hudson	NULL
GS	NULL
,	NULL
Bankier	NULL
SC	NULL
,	NULL
Satchwell	NULL
and	NULL
Barrell	NULL
BG	NULL
(	NULL
1985	NULL
)	NULL
The	NULL
short	NULL
unique	NULL
region	NULL
of	NULL
the	NULL
B95.8	NULL
Epstein-Barr	NULL
virus	NULL
genome	NULL
.	NULL

Virology	NULL
147	NULL
:	NULL
81-85	NULL
Iwatsuki	NULL
K	NULL
,	NULL
Ohtsuka	NULL
M	NULL
,	NULL
Harada	NULL
H	NULL
,	NULL
Han	NULL
G	NULL
and	NULL
Kaneko	NULL
F	NULL
(	NULL
1997	NULL
)	NULL
Clinicopathologic	NULL
manifestations	NULL
of	NULL
Epstein-Barr	NULL
virus-associated	NULL
cutaneous	NULL
lymphoproliferative	NULL
disorders	NULL
.	NULL

Arch	NULL
Dermatol	NULL
133	NULL
:	NULL
1081-1086	NULL
Jaffe	NULL
ES	NULL
,	NULL
Costa	NULL
J	NULL
,	NULL
Fauci	NULL
AS	NULL
,	NULL
Cossman	NULL
J	NULL
and	NULL
Tsokos	NULL
M	NULL
(	NULL
1983	NULL
)	NULL
Malignant	NULL
lymphoma	NULL
and	NULL
erythrophagocytosis	NULL
simulating	NULL
malignant	NULL
histiocytosis	NULL
.	NULL

Am	NULL
J	NULL
Med	NULL
75	NULL
:	NULL
741-749	NULL
©2001	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
EB	NULL
virus	NULL
antigen	NULL
expression	NULL
by	NULL
NK/T-cell	NULL
lymphomas	NULL
925	NULL
Jaffe	NULL
ES	NULL
,	NULL
Chan	NULL
JKC	NULL
,	NULL
Su	NULL
IJ	NULL
,	NULL
Frizzera	NULL
G	NULL
,	NULL
Mori	NULL
S	NULL
,	NULL
Feller	NULL
AC	NULL
and	NULL
Ho	NULL
FCS	NULL
(	NULL
1996	NULL
)	NULL
Report	NULL
of	NULL
the	NULL
workshop	NULL
on	NULL
nasal	NULL
and	NULL
related	NULL
extranodal	NULL
angiocentric	NULL
T/natural	NULL
killer	NULL
cell	NULL
lymphomas	NULL
.	NULL

Am	NULL
J	NULL
Surg	NULL
Pathol	NULL
20	NULL
:	NULL
103-111	NULL
Kerr	NULL
BM	NULL
,	NULL
Lear	NULL
AL	NULL
,	NULL
Rowe	NULL
M	NULL
,	NULL
Croom-Carter	NULL
D	NULL
,	NULL
Young	NULL
LS	NULL
,	NULL
Rookes	NULL
SM	NULL
,	NULL
Gallimore	NULL
PH	NULL
and	NULL
Rickinson	NULL
AB	NULL
(	NULL
1992	NULL
)	NULL
Three	NULL
transcriptionally	NULL
distinct	NULL
forms	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
latency	NULL
in	NULL
somatic	NULL
cells	NULL
hybrids	NULL
:	NULL
cell	NULL
phenotype	NULL
dependence	NULL
of	NULL
viral	NULL
promotoer	NULL
usage	NULL
.	NULL

Virology	NULL
187	NULL
:	NULL
189-201	NULL
Levitskaya	NULL
J	NULL
,	NULL
Coram	NULL
M	NULL
,	NULL
Levitsky	NULL
V	NULL
,	NULL
Imreh	NULL
S	NULL
,	NULL
Steigerwald-Mullen	NULL
PM	NULL
,	NULL
Klein	NULL
G	NULL
,	NULL
Kurilla	NULL
MG	NULL
and	NULL
Masucci	NULL
MG	NULL
(	NULL
1995	NULL
)	NULL
Inhibition	NULL
of	NULL
antigen	NULL
processing	NULL
by	NULL
the	NULL
internal	NULL
repeat	NULL
region	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen-1	NULL
.	NULL

Nature	NULL
375	NULL
:	NULL
685-688	NULL
Miller	NULL
G	NULL
(	NULL
1990	NULL
)	NULL
The	NULL
switch	NULL
between	NULL
latency	NULL
and	NULL
replication	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

J	NULL
Infect	NULL
Dis	NULL
161	NULL
:	NULL
833-844	NULL
Miyazaki	NULL
I	NULL
,	NULL
Cheung	NULL
RK	NULL
and	NULL
Dosch	NULL
HM	NULL
(	NULL
1993	NULL
)	NULL
Viral	NULL
interleukin	NULL
10	NULL
is	NULL
critical	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
B	NULL
cell	NULL
growth	NULL
transformation	NULL
by	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
178	NULL
:	NULL
439-447	NULL
Moore	NULL
KW	NULL
,	NULL
Vieira	NULL
P	NULL
,	NULL
Fiorentino	NULL
DF	NULL
,	NULL
Trounstine	NULL
ML	NULL
,	NULL
Khan	NULL
TA	NULL
and	NULL
Mosmann	NULL
TR	NULL
(	NULL
1990	NULL
)	NULL
Homology	NULL
of	NULL
cytokine	NULL
synthesis	NULL
inhibitory	NULL
factor	NULL
(	NULL
IL-10	NULL
)	NULL
to	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
gene	NULL
BCRF1	NULL
.	NULL

Science	NULL
248	NULL
:	NULL
1230-1234	NULL
Ohtsuka	NULL
M	NULL
,	NULL
Iwatsuki	NULL
K	NULL
,	NULL
Kaneko	NULL
R	NULL
,	NULL
Akiba	NULL
H	NULL
,	NULL
Kikuchi	NULL
S	NULL
,	NULL
Harada	NULL
H	NULL
and	NULL
Kaneko	NULL
F	NULL
(	NULL
1999	NULL
)	NULL
Epstein-Barr	NULL
virus-associated	NULL
lymphoid	NULL
hyperplasia	NULL
of	NULL
the	NULL
eyelid	NULL
characterized	NULL
by	NULL
intramuscular	NULL
infiltration	NULL
.	NULL

Br	NULL
J	NULL
Dermatol	NULL
140	NULL
:	NULL
358-359	NULL
Oudejans	NULL
JJ	NULL
,	NULL
Jiwa	NULL
M	NULL
,	NULL
van	NULL
den	NULL
Brule	NULL
AJC	NULL
,	NULL
Grasser	NULL
FA	NULL
,	NULL
Horstman	NULL
A	NULL
,	NULL
Vos	NULL
W	NULL
,	NULL
Kluin	NULL
PM	NULL
,	NULL
van	NULL
der	NULL
Valk	NULL
P	NULL
,	NULL
Walboomers	NULL
JMM	NULL
and	NULL
Meijer	NULL
CJLM	NULL
(	NULL
19952	NULL
)	NULL
Detection	NULL
of	NULL
heterogencous	NULL
Epstein-Barr	NULL
virus	NULL
gene	NULL
expression	NULL
patterns	NULL
within	NULL
individual	NULL
post-transplanation	NULL
lymphoproliferative	NULL
disorders	NULL
.	NULL

Am	NULL
J	NULL
Pathol	NULL
147	NULL
:	NULL
923-933	NULL
Oudejans	NULL
JJ	NULL
,	NULL
van	NULL
den	NULL
Brule	NULL
AJC	NULL
,	NULL
Jiwa	NULL
NM	NULL
,	NULL
de	NULL
Bruin	NULL
PC	NULL
,	NULL
Ossenkoppele	NULL
GJ	NULL
,	NULL
van	NULL
der	NULL
Valk	NULL
P	NULL
,	NULL
Walboomers	NULL
JMM	NULL
and	NULL
Meijer	NULL
CJLM	NULL
(	NULL
1995b	NULL
)	NULL
BHRF1	NULL
,	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
homologue	NULL
of	NULL
the	NULL
Bel-2	NULL
proto-oncogene	NULL
,	NULL
is	NULL
transcribed	NULL
in	NULL
EBV-associated	NULL
B-cell	NULL
lymphomas	NULL
and	NULL
in	NULL
reactive	NULL
lymphocytes	NULL
.	NULL

Blood	NULL
86	NULL
:	NULL
1893-1902	NULL
Raab-Traub	NULL
N	NULL
and	NULL
Flynn	NULL
K	NULL
(	NULL
1986	NULL
)	NULL
The	NULL
structure	NULL
of	NULL
the	NULL
termini	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
as	NULL
a	NULL
marker	NULL
of	NULL
clonal	NULL
cellular	NULL
proliferation	NULL
.	NULL

Cell	NULL
47	NULL
:	NULL
883-889	NULL
Rickinson	NULL
AB	NULL
,	NULL
Young	NULL
LS	NULL
and	NULL
Rowe	NULL
M	NULL
(	NULL
1987	NULL
)	NULL
Influence	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
EBNA2	NULL
on	NULL
the	NULL
growth	NULL
phenotype	NULL
of	NULL
virus-transformed	NULL
B	NULL
cells	NULL
.	NULL

J	NULL
Virol	NULL
61	NULL
:	NULL
1310-1317	NULL
Rowe	NULL
M	NULL
,	NULL
Rowe	NULL
DT	NULL
,	NULL
Gregory	NULL
CD	NULL
,	NULL
Young	NULL
LS	NULL
,	NULL
Farrell	NULL
PJ	NULL
,	NULL
Rupani	NULL
H	NULL
and	NULL
Rickinson	NULL
AB	NULL
(	NULL
1987	NULL
)	NULL
Differences	NULL
in	NULL
B	NULL
cell	NULL
growth	NULL
phenotype	NULL
reflect	NULL
novel	NULL
patterns	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
latent	NULL
gene	NULL
expression	NULL
in	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cells	NULL
.	NULL

EMBO	NULL
J	NULL
6	NULL
:	NULL
2743-2751	NULL
Sample	NULL
J	NULL
,	NULL
Brooks	NULL
L	NULL
,	NULL
Sample	NULL
C	NULL
,	NULL
Young	NULL
LS	NULL
,	NULL
Rowe	NULL
M	NULL
,	NULL
Gregory	NULL
C	NULL
,	NULL
Rickinson	NULL
AB	NULL
and	NULL
Kieff	NULL
E	NULL
(	NULL
1991	NULL
)	NULL
Restricted	NULL
Epstein-Barr	NULL
virus	NULL
protein	NULL
expression	NULL
in	NULL
Burkitt	NULL
lymphoma	NULL
is	NULL
due	NULL
to	NULL
a	NULL
different	NULL
Epstein-Barr	NULL
nuclear	NULL
antigen	NULL
1	NULL
transcriptional	NULL
initiation	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
88	NULL
:	NULL
6343-6347	NULL
Schaefer	NULL
BC	NULL
,	NULL
Woisetschlaeger	NULL
M	NULL
,	NULL
Strominger	NULL
JL	NULL
and	NULL
Speck	NULL
SH	NULL
(	NULL
1991	NULL
)	NULL
Exclusive	NULL
expression	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
1	NULL
in	NULL
Burkitt	NULL
lymphoma	NULL
arises	NULL
from	NULL
a	NULL
third	NULL
promoter	NULL
,	NULL
distinct	NULL
from	NULL
the	NULL
promoters	NULL
used	NULL
in	NULL
latently	NULL
infected	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
88	NULL
:	NULL
6550-6554	NULL
Su	NULL
IJ	NULL
and	NULL
Hsich	NULL
HC	NULL
(	NULL
1992	NULL
)	NULL
Clinicopathological	NULL
spectrum	NULL
of	NULL
Epstein-Barr	NULL
virus-associated	NULL
T	NULL
cell	NULL
malignancies	NULL
.	NULL

Leukemia	NULL
Lymphoma	NULL
7	NULL
:	NULL
47-53	NULL
Su	NULL
IJ	NULL
,	NULL
Hsich	NULL
HC	NULL
,	NULL
Lin	NULL
KH	NULL
,	NULL
Kao	NULL
WCL	NULL
,	NULL
Chen	NULL
CL	NULL
,	NULL
Cheng	NULL
AL	NULL
,	NULL
Kadin	NULL
ME	NULL
and	NULL
Chen	NULL
JY	NULL
(	NULL
1991	NULL
)	NULL
Aggressive	NULL
peripheral	NULL
T-cell	NULL
lymphoma	NULL
containing	NULL
Epstein-Barr	NULL
virus	NULL
DNA	NULL
:	NULL
A	NULL
clinical	NULL
,	NULL
pathologic	NULL
and	NULL
molecular	NULL
analysis	NULL
.	NULL

Blood	NULL
77	NULL
:	NULL
799-808	NULL
Sugiura	NULL
M	NULL
,	NULL
Imai	NULL
S	NULL
,	NULL
Tokunaga	NULL
M	NULL
,	NULL
Koizumi	NULL
S	NULL
,	NULL
Uchizawa	NULL
M	NULL
,	NULL
Okamoto	NULL
K	NULL
and	NULL
Osato	NULL
T	NULL
(	NULL
1996	NULL
)	NULL
Transcription	NULL
analysis	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
gene	NULL
expression	NULL
in	NULL
EBV	NULL
positive	NULL
gastric	NULL
carcinoma	NULL
:	NULL
unique	NULL
viral	NULL
latency	NULL
in	NULL
the	NULL
tumour	NULL
cells	NULL
.	NULL

Br	NULL
J	NULL
Cancer	NULL
74	NULL
;	NULL
625-631	NULL
Tao	NULL
Q	NULL
,	NULL
Robertson	NULL
KD	NULL
,	NULL
Manns	NULL
A	NULL
,	NULL
Hildesheim	NULL
A	NULL
and	NULL
Ambinder	NULL
RF	NULL
(	NULL
1998	NULL
)	NULL
Epstein-Barr	NULL
virus	NULL
in	NULL
endemic	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
:	NULL
molecular	NULL
analysis	NULL
of	NULL
primary	NULL
tumour	NULL
tissue	NULL
.	NULL

Blood	NULL
91	NULL
:	NULL
1373-1381	NULL
Wang	NULL
D	NULL
,	NULL
Liebowitz	NULL
D	NULL
and	NULL
Kieff	NULL
E	NULL
(	NULL
1985	NULL
)	NULL
An	NULL
EBV	NULL
membrane	NULL
protein	NULL
expressed	NULL
in	NULL
immortalized	NULL
lymphocytes	NULL
transforms	NULL
established	NULL
rodent	NULL
cells	NULL
.	NULL

Cell	NULL
43	NULL
:	NULL
831-840	NULL
Xu	NULL
ZG	NULL
,	NULL
Iwatsuki	NULL
K	NULL
,	NULL
Ohtsuka	NULL
M	NULL
,	NULL
Oyama	NULL
N	NULL
,	NULL
Matsui	NULL
T	NULL
and	NULL
Kaneko	NULL
F	NULL
(	NULL
2000	NULL
)	NULL
Polymorphism	NULL
analysis	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
isolates	NULL
from	NULL
patients	NULL
with	NULL
cutaneous	NULL
NK/T-cell	NULL
lymphoproliferative	NULL
disorders	NULL
:	NULL
a	NULL
possible	NULL
relation	NULL
to	NULL
the	NULL
endemic	NULL
occurrence	NULL
of	NULL
these	NULL
diseases	NULL
in	NULL
Japan	NULL
.	NULL

J	NULL
Med	NULL
Virol	NULL
62	NULL
:	NULL
239-246	NULL
Young	NULL
LS	NULL
,	NULL
Alfieri	NULL
C	NULL
,	NULL
Hennessy	NULL
K	NULL
,	NULL
Evans	NULL
H	NULL
,	NULL
Ohara	NULL
C	NULL
,	NULL
Anderson	NULL
KC	NULL
,	NULL
Ritz	NULL
J	NULL
,	NULL
Shapiro	NULL
RS	NULL
,	NULL
Rockinson	NULL
A	NULL
and	NULL
Kieff	NULL
E	NULL
(	NULL
1989	NULL
)	NULL
Expression	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
transformation-associated	NULL
genes	NULL
in	NULL
tissues	NULL
of	NULL
patients	NULL
with	NULL
EBV	NULL
lymphoproliferative	NULL
disease	NULL
.	NULL

N	NULL
Eng	NULL
!	NULL

J	NULL
Med	NULL
321	NULL
:	NULL
1080-1085	NULL
Zeidler	NULL
R	NULL
,	NULL
Eissner	NULL
G	NULL
,	NULL
Meissner	NULL
P	NULL
,	NULL
Uebel	NULL
S	NULL
,	NULL
Tamp	NULL
R	NULL
,	NULL
Lazis	NULL
S	NULL
and	NULL
Hammerschmidt	NULL
W	NULL
(	NULL
1997	NULL
)	NULL
Downregulation	NULL
of	NULL
TAP1	NULL
in	NULL
B	NULL
lymphocytes	NULL
by	NULL
cellular	NULL
and	NULL
Epstein-Barr	NULL
virus-encoded	NULL
interleukin-10	NULL
.	NULL

Blood	NULL
90	NULL
:	NULL
2390-2397	NULL
British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
2001	NULL
)	NULL
84	NULL
(	NULL
7	NULL
)	NULL
,	NULL
920-925	NULL

